European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
November 1, 2022
Marco Solmi, Chaomei Chen, Charles Daure et al.
55 citations
Over the past century, clinical research on psychedelics has evolved from an early focus on safety into a 'psychedelic renaissance' after the 1990s. A scientometric analysis of 31,687 documents from the Web of Science identified major research themes: hallucinogens/entheogens, entactogens, novel psychoactive substances (NPS), and dissociative substances. The field has shifted from basic science to clinical applications, including phase 2 and 3 trials and evidence synthesis. Recent trends include NPS, ketamine-associated brain changes, and ayahuasca-assisted psychotherapy. The USA and Canada lead in productivity, reflecting legislative influences. This translational evolution has already led to esketamine approval for depression and may lead to further approvals across mental and physical conditions. Toxicology screening tools for NPS are urgently needed and may follow a similar path.
BMC psychiatry
January 26, 2024
Laetitia Vanderijst, Felix Hever, Anne Buot et al.
11 citations
A proposed clinical trial will test whether adding psilocybin-assisted therapy to inpatient rehabilitation for severe alcohol use disorder is feasible and effective. In a double-blind, randomized, placebo-controlled phase II trial, 62 participants aged 21–64 will receive either a high dose (30 mg) or an active placebo dose (5 mg) of psilocybin alongside a brief psychotherapy based on acceptance and commitment therapy. The main outcome is the difference in heavy drinking days from baseline to four weeks after hospital discharge. Secondary outcomes include drinking behavior up to six months, mental health symptoms, neuroplasticity, and cognitive mechanisms. The trial is registered as EudraCT 2022-002369-14 and NCT06160232.
Research Square (Research Square)
January 4, 2024
Laetitia Vanderijst, Felix Hever, Anne Buot et al.
A proposed double-blind, randomized, placebo-controlled phase II trial will test whether adding psilocybin-assisted therapy to a 4-week inpatient rehabilitation program for severe alcohol use disorder is feasible and clinically effective. Sixty-two participants aged 21–64 years will receive either a high dose (30 mg) or an active placebo dose (5 mg) of psilocybin, both paired with a brief acceptance and commitment therapy intervention. The primary clinical outcome is the change in percentage of heavy drinking days from baseline to four weeks after hospital discharge. Secondary outcomes include drinking behavior up to six months, symptoms of depression and anxiety, neuroplasticity, and changes in neurocognitive systems linked to addiction.